Our 3D InSight™ Patient-derived Primary Tumor Spheroid Platform revolutionizes preclinical oncology by accurately mirroring patient-specific genomic diversity, complexity of the tumor microenvironment and clinically relevant drug responsiveness – transforming in vitro modeling into predictive insights that align seamlessly with in vivo patient outcomes.
Built on the foundation of InSphero’s expertise with primary tissue models and scalable platforms, these models offer predictive, robust, and reproducible results for informed decision-making.
All preclinical models, from cell lines to patient-derived xenografts (PDXs) serve a purpose in the spectrum of early discovery. However, they all fail to capture the intra- and inter-tumor complexity of tumors in vivo. Our patient-derived primary tumor spheroids overcome these limitations by:
Patient-derived tumor spheroids retain the architecture and complexity of the original tumor tissue, as confirmed by immunohistochemistry (IHC) for all resident cell populations. This ensures physiological and biological relevance for drug screening applications.
Therapeutic testing across multiple patient-derived tumor spheroids using automation-compatible Akura™ 96 and 384 well plates with high-dimensional, high throughput readouts.
Consistent composition and size of Patient-derived Primary tumor spheroids enable robust and reproducible therapeutic screening across oncology applications.
Conventional, 2D-monolayer cell line-derived tumor models produce generic oncology readouts for viability. The outdated flat biology, which is not representative of tumor and patient heterogeneity is unable to fully capture the unpredictable progression of a complex disease like cancer.
Our 3D InSight™ Oncology platform provides human-derived 3D tumor models that enable you to study cellular interaction in a 3D environment. Our technology enhances the ability to assess various phenotypic characteristics that can accurately predict different aspects of in vivo biology.
Our scalable, reliable and reproducible 3D tumor models allow you to study intracellular interactions and the effect of the tumor micro environment (TME) on therapeutic resistance and susceptibility. Our ability to multiplex imaging, biochemical and morphological read outs ensure that you maximize the information you get out of a single tumor spheroid in the context of its TME. Our platform is compatible with many therapeutic modalities including but not limited to small molecules, biologics, protein therapeutics and siRNAs. Each modality is validated on the 3D InSight ™ tumor spheroid platform for biological and technical activity.
Enhance your drug investigation by using our scalable 3D InSight™ Oncology & Immunology platform, reproducing the complex tumor micro-environment.
Fill in form below to contact our 3D in vitro experts
Get the latest news on 3D in vitro research
Fill in the form below to view this resource
